Health, Fitness & Food

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks rose Monday, though they’re still having a rough August. Nvidia (NVDA), which has been slumping recently, jumped about 5.5% to start the week. Morgan Stanley reiterated Nvidia
0 Comments
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters LONDON — Popular weight-loss drug Wegovy could be made available under more health insurance schemes, after the results of a late-stage trial pointed to the drug’s efficacy in
0 Comments
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Back-to-back losses Still believe in Disney Eli Lilly keeps going 1. Back-to-back losses U.S. stocks on Wednesday were sinking for the second straight session ahead of this week’s key inflation
0 Comments
In this article LLY NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023.  Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a
0 Comments
In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio.  The deal is Novo Nordisk’s latest attempt to
0 Comments
In this article ILMN Follow your favorite stocksCREATE FREE ACCOUNT A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021. Mike Blake | Reuters The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA
0 Comments
In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023.  Jim Vondruska | Reuters Novo Nordisk, which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported
0 Comments
Organizers celebrate the defeat of Issue 1 during an election night party at the Columbus Fire Fighters Local 67 on Tuesday, Aug. 8, 2023 in Columbus, Ohio. Ohio voters have rejected a proposal that would’ve made it more difficult for voters to amend the state constitution, including one measure set for the November ballot that
0 Comments
In this article AMZN Follow your favorite stocksCREATE FREE ACCOUNT Amazon, the United States’ second-largest employer, will now offer fertility and family planning services to employees through a partnership with Maven Clinic. The free offering will be available to more than 1 million eligible Amazon employees spread across 50 countries outside of the U.S. and
0 Comments
In this article SAGE BIIB Follow your favorite stocksCREATE FREE ACCOUNT In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images Shares of Sage Therapeutics fell more than 50% on Monday after the Food
0 Comments
In this article GSK-GB GSK PFE Follow your favorite stocksCREATE FREE ACCOUNT Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine.  GSK claims New York-based Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen
0 Comments
Humana (HUM) reported second-quarter results Wednesday that were much better than feared, sending its stock price soaring and giving us the confidence to stick with the jilted health insurer. Revenue for the three months ended June 30 rose 13% year-over-year, to $26.75 billion, exceeding analysts’ estimates of $26.23 billion, according to Refinitiv. Adjusted earnings-per-share (EPS)
0 Comments
In this article MRNA Follow your favorite stocksCREATE FREE ACCOUNT Artur Widak | Nurphoto | Getty Images Shares of Moderna rose Thursday after the biotech company hiked its full-year outlook for its Covid vaccine, its only marketable product, despite reporting a quarterly loss and sharp drop in revenue.  The biotech company generated second-quarter sales of
0 Comments